Mark Cuban’s Cost Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling Right Now
Big Pharma vs. Cost-Plus isn’t a debate—it’s a modeling problem.
Mark Cuban’s Cost Plus Drugs has become the latest flashpoint in the U.S. drug pricing war. But if you’re an investor, operator, policy professional, or healthcare strategist, the real …
